Global & Regional Health Technology Assessment最新文献_第6页

La territorializzazione del farmaco in epoca di PNRR: prospettive, opportunità e spunti di riflessione da un panel di esperti. PNRR 时代的毒品属地化：专家小组的观点、机遇和见解。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-12-05 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2495

Anna Maria Marata, Walter Marrocco, Emanuela Arcangeli, Mattia Battistini, Giuliano Buzzetti, Riccardo Candido, Gianluigi Casadei, Francesco Cattel, Arturo Cavaliere, Agostino Consoli, Giovanni Corrao, Guido Didoni, Mauro Di Gesù, Alberto Giovanzana, Matteo Lenzi, Massimo Medaglia, Marta Meloncelli, Stefano Palcic, Marcello Pani, Francesca Patarnello, Emanuele Pria, Dario Scaduto, Valeria Tozzi, Marco Zibellini, Elisa Crovato

引用次数: 0

Costo per responder del metotrexato rispetto ad altre terapie in pazienti con psoriasi a placche da moderata a grave in Italia. 意大利中重度斑块状银屑病患者使用甲氨蝶呤与其他疗法相比，每个应答者的成本。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-11-10 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2474

Giuseppe Pompilio, Davide Integlia

引用次数: 0

La gestione del trattamento del paziente con diagnosi di Lupus Eritematoso Sistemico: un’analisi di consenso Delphi. 系统性红斑狼疮患者的治疗管理：德尔菲共识分析。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-10-10 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2470

Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria

引用次数: 0

Il valore generato dall’effetto moltiplicatore degli investimenti dell’industria del farmaco in Italia: proposte di riforma per favorire competitività e attrattività. 意大利制药业投资乘数效应产生的价值：促进竞争力和吸引力的改革建议。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-10-05 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2440

Francesca Patarnello, Emiliano Briante, Federico Villa

引用次数: 0

Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. 西班牙晚期非小细胞肺癌患者 ALK 诊断与非诊断的成本效益分析。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-09-12 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2449

Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo

{"title":"Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain.","authors":"Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo","doi":"10.33393/grhta.2022.2449","DOIUrl":"10.33393/grhta.2022.2449","url":null,"abstract":"Introduction: In recent years, target therapies to specific molecular alterations in advanced non-small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheless, ALK diagnosis is not performed in all NSCLC patients in Spain. The objective of this study is to estimate in monetary terms the benefit for the Spanish society of ALK diagnosis in advanced NSCLC patients.Methods: A cost-benefit analysis of ALK diagnosis vs. non-diagnosis in advanced NSCLC patients was carried out from the Spanish social perspective, with a time horizon of 5 years. Costs, benefits and the cost-benefit ratio were measured. The analysis has considered the overall survival in advanced NSCLC patients treated with the ALK-tyrosine kinase inhibitor (TKI) alectinib. The natural history of NSCLC was simulated using a Markov model. A 3% discount rate was applied to both costs and benefits. The result was tested using a deterministic sensitivity analysis.Results: The cost of ALK diagnosis vs. non-diagnosis in the base case would be €10.19 million, generating benefits of €11.71 million. The cost-benefit ratio would be €1.15. In the sensitivity analysis, the cost-benefit ratio could range from €0.89 to €2.10.Conclusions: The results justify the universal application of ALK diagnosis in advanced NSCLC, which generates a benefit for Spanish society that outweighs its costs and allows optimal treatment with targeted therapies for these patients.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"9 ","pages":"82-90"},"PeriodicalIF":0.4,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/ba/grhta-9-82.PMC9793412.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10511648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential impact of PNNR on the management of patients with epilepsy. PNNR 对癫痫患者管理的潜在影响。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-06-28 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2445

Francesco Saverio Mennini

引用次数: 0

Approccio diagnostico e terapeutico al paziente con sindrome coronarica acuta. 急性冠状动脉综合征患者的诊断和治疗方法。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-05-24 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2389

Fabrizio Ricci, Federico Archilletti, Raffaele De Caterina

引用次数: 0

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy. 勘误：意大利中重度类风湿性关节炎患者中，达帕替尼与阿帕他赛的每次应答成本。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-02-17 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2383

Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi

引用次数: 0

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update. 意大利治疗血友病 B 的延长半衰期重组因子 IX 产品的成本分析：最新情况。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2022-01-19 eCollection Date: 2022-01-01 DOI: 10.33393/grhta.2022.2331

Andrea Aiello, Maria E Mancuso, Serena Leone, Letizia Rossi, Lorenzo Cioni, Cristina Teruzzi

{"title":"Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update.","authors":"Andrea Aiello, Maria E Mancuso, Serena Leone, Letizia Rossi, Lorenzo Cioni, Cristina Teruzzi","doi":"10.33393/grhta.2022.2331","DOIUrl":"10.33393/grhta.2022.2331","url":null,"abstract":"Haemophilia B (HB) is a rare disease which may lead to chronic disabling arthropathy, resulting in a significant clinical, social and economic impact. In recent years, new extended half-life (EHL) factor IX concentrates produced by recombinant technology (rFIX) have been developed. They have shown significantly prolonged half-life as compared to other rFIX products and improved bleeding control when used as prophylaxis. To date, EHL rFIX products reimbursed in Italy are a recombinant coagulation factor IX produced with Fc technology (rFIXFc) and a recombinant fusion protein containing rFIX fused with recombinant albumin (rIX-FP). The results of extension studies with injection intervals with a median of almost every 14 days for the complete individualized interval prophylaxis (IP) group on rFIXFc and 21 days for a selected subgroup of patients on rIX-FP have recently been published. The aim of this analysis was to estimate the cost of prophylactic treatment with rFIXFc and rIX-FP in adult patients, in the light of new clinical evidence and current average prices in Italy. The cost of therapy was estimated on the basis of the results of extension studies, the average prices reported in regional drug tenders and assuming an average patient weight of 70 kg. The analysis estimated a cost per patient/year between €224,407 and €230,355 for rFIXFc and between €242,259 and €368,587 for rIX-FP. The sensitivity analysis confirmed the robustness of the results. The use of rFIXFc over rIX-FP proves to be the least expensive choice for the treatment of HB in Italy.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"9 ","pages":"9-13"},"PeriodicalIF":0.4,"publicationDate":"2022-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/ce/grhta-9-9.PMC9768593.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10521006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disability weights for castration-resistant prostate cancer: an empirical investigation. 去势抵抗性前列腺癌的残疾权重:一项实证研究。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2022-01-01 DOI: 10.33393/grhta.2022.2431

Ludovica Borsoi, Oriana Ciani, Rocco De Vivo, Giorgio Ivan Russo, Marcello Scarcia, Chiara De Fino, Patrizia Beccaglia, Irene Luccarini

{"title":"Disability weights for castration-resistant prostate cancer: an empirical investigation.","authors":"Ludovica Borsoi, Oriana Ciani, Rocco De Vivo, Giorgio Ivan Russo, Marcello Scarcia, Chiara De Fino, Patrizia Beccaglia, Irene Luccarini","doi":"10.33393/grhta.2022.2431","DOIUrl":"https://doi.org/10.33393/grhta.2022.2431","url":null,"abstract":"Introduction: Health state valuation and diagnostic-therapeutic pathways at the junction between non-metastatic and metastatic castration-resistant prostate cancer (CRPC) are not well documented. We aimed at: (i) estimating the disability weights (DWs) for health states across a continuum of disease from asymptomatic non-metastatic (nmCRPC) to symptomatic metastatic state (mCRPC); (ii) mapping the diagnostic-therapeutic pathway of nmCRPC in Italy.Methods: Structured qualitative interviews were performed with clinical experts to gather information on nmCRPC clinical pathway. An online survey was administered to clinical experts to estimate DWs for four CRPC health states defined from interviews and literature review (i.e., nmCRPC, asymptomatic mCRPC, symptomatic mCRPC, mCRPC in progression during or after chemotherapy). Clinicians' preferences for health states were elicited using the Person-Trade-Off (PTO) and Visual Analogue Scale (VAS) methods. DWs associated with each health state, from 0 (best imaginable health state) and 1 (worst imaginable health state), were estimated.Results: We found that the management of nmCRPC is heterogeneous across Italian regions and hospitals, especially with respect to diagnostic imaging techniques. DWs for PTO ranged from 0.415 (95% confidence interval [CI] 0.208-0.623) in nmCRPC to 0.740 (95% CI 0.560-0.920) in mCRPC, in progression during or after chemotherapy. DWs for VAS ranged between 0.246 (95% CI 0.131-0.361) in nmCRPC to 0.689 (95% CI 0.583-0.795) in mCRPC, in progression during or after chemotherapy.Conclusions: Estimated DWs suggest that delaying transition to a metastatic state might ease the disease burden at both patient and societal levels.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"9 ","pages":"146-154"},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/f3/grhta-9-146.PMC9668063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9084273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0